Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)

JP Delord, et al.
ASCO 2022
Abstract available on the ASCO website – Download the poster here
Poster Presentation